Tan F - Search Results

Year	Number of Results
1957	1
1960	1
1977	1
1980	1
1981	3
1982	2
1983	3
1984	3
1985	3
1986	2
1987	4
1988	5
1989	4
1990	5
1991	3
1992	5
1993	3
1994	3
1995	5
1996	3
1997	4
1998	6
1999	11
2000	17
2001	17
2002	24
2003	13
2004	27
2005	49
2006	38
2007	27
2008	34
2009	45
2010	73
2011	72
2012	82
2013	96
2014	110
2015	128
2016	122
2017	117
2018	139
2019	155
2020	230
2021	242
2022	258
2023	238
2024	253
2025	1

1

Biochanin A protects against iron overload associated knee osteoarthritis via regulating iron levels and NRF2/System xc-/GPX4 axis.

He Q, Yang J, Pan Z, Zhang G, Chen B, Li S, Xiao J, Tan F, Wang Z, Chen P, Wang H. He Q, et al. Among authors: tan f. Biomed Pharmacother. 2023 Jan;157:113915. doi: 10.1016/j.biopha.2022.113915. Epub 2022 Nov 12. Biomed Pharmacother. 2023. PMID: 36379122 Free article.

2

Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer.

Guo W, Zhou B, Bie F, Huai Q, Xue X, Guo L, Tan F, Xue Q, Zhao L, Gao S. Guo W, et al. Among authors: tan f. Clin Transl Med. 2023 Oct;13(10):e1453. doi: 10.1002/ctm2.1453. Clin Transl Med. 2023. PMID: 37846760 Free PMC article.

3

AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness.

Qi J, Tan F, Zhang L, Lu L, Zhang S, Zhai Y, Lu Y, Qian X, Dong W, Zhou Y, Zhang Z, Yang X, Jiang L, Yu C, Liu J, Chen T, Wu L, Tan C, Sun S, Song H, Shu Y, Xu L, Gao X, Li H, Chai R. Qi J, et al. Among authors: tan f. Adv Sci (Weinh). 2024 Mar;11(11):e2306788. doi: 10.1002/advs.202306788. Epub 2024 Jan 8. Adv Sci (Weinh). 2024. PMID: 38189623 Free PMC article.

4

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.

Yu JJ, Zhou DD, Yang XX, Cui B, Tan FW, Wang J, Li K, Shang S, Zhang C, Lv XX, Zhang XW, Liu SS, Yu JM, Wang F, Huang B, Hua F, Hu ZW. Yu JJ, et al. Among authors: tan fw. Nat Commun. 2020 Jul 21;11(1):3660. doi: 10.1038/s41467-020-17385-0. Nat Commun. 2020. PMID: 32694521 Free PMC article.

5

One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study.

Li N, Tan F, Chen W, Dai M, Wang F, Shen S, Tang W, Li J, Yu Y, Cao W, Xu Y, Qin C, Zhao L, Zhu M, Guo L, Wu Z, Yang Z, Zheng Y, Chen H, Liu Y, Wei D, Dong D, Cao J, Zhang S, Yan S, Wang N, Du L, Shen H, Wu N, He J; National Lung Cancer Screening programme group. Li N, et al. Among authors: tan f. Lancet Respir Med. 2022 Apr;10(4):378-391. doi: 10.1016/S2213-2600(21)00560-9. Epub 2022 Mar 8. Lancet Respir Med. 2022. PMID: 35276087

6

Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in China.

Wang F, Tan F, Shen S, Wu Z, Cao W, Yu Y, Dong X, Xia C, Tang W, Xu Y, Qin C, Zhu M, Li J, Yang Z, Zheng Y, Luo Z, Zhao L, Li J, Ren J, Shi J, Huang Y, Wu N, Shen H, Chen W, Li N, He J. Wang F, et al. Among authors: tan f. Am J Respir Crit Care Med. 2023 Jan 1;207(1):77-88. doi: 10.1164/rccm.202204-0727OC. Am J Respir Crit Care Med. 2023. PMID: 35900139

7

Large-scale tethered function assays identify factors that regulate mRNA stability and translation.

Luo EC, Nathanson JL, Tan FE, Schwartz JL, Schmok JC, Shankar A, Markmiller S, Yee BA, Sathe S, Pratt GA, Scaletta DB, Ha Y, Hill DE, Aigner S, Yeo GW. Luo EC, et al. Among authors: tan fe. Nat Struct Mol Biol. 2020 Oct;27(10):989-1000. doi: 10.1038/s41594-020-0477-6. Epub 2020 Aug 17. Nat Struct Mol Biol. 2020. PMID: 32807991 Free PMC article.

8

Wild-type IDH1 maintains NSCLC stemness and chemoresistance through activation of the serine biosynthetic pathway.

Zhang C, Yu JJ, Yang C, Yuan ZL, Zeng H, Wang JJ, Shang S, Lv XX, Liu XT, Liu J, Xue Q, Cui B, Tan FW, Hua F. Zhang C, et al. Among authors: tan fw. Sci Transl Med. 2023 Dec 13;15(726):eade4113. doi: 10.1126/scitranslmed.ade4113. Epub 2023 Dec 13. Sci Transl Med. 2023. PMID: 38091408

9

Diabetes exacerbated sepsis-induced intestinal injury by promoting M1 macrophage polarization via miR-3061/Snail1 signaling.

Tan F, Cao Y, Zheng L, Wang T, Zhao S, Chen J, Pang C, Xia W, Xia Z, Li N, Chi X. Tan F, et al. Front Immunol. 2022 Sep 9;13:922614. doi: 10.3389/fimmu.2022.922614. eCollection 2022. Front Immunol. 2022. PMID: 36159784 Free PMC article.

10

Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.

Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L, Mao Y, Tan F, Gao Y, Wu N, Ying J, Xue Q, Li N, Gao S, He J. Zhao J, et al. Among authors: tan f. J Thorac Oncol. 2023 Jun;18(6):780-791. doi: 10.1016/j.jtho.2023.02.019. Epub 2023 Mar 2. J Thorac Oncol. 2023. PMID: 36870519 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,416 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,416 results

Results by year